Filing Flows › Comparisons › LNTH vs MYGN
Lantheus Holdings vs Myriad Genetics: LNTH and MYGN compared
Lantheus Holdings is the larger company: $390M of revenue in its latest quarter (Q3 2026) against $203M for Myriad Genetics (Q3 2026). Lantheus Holdings is growing faster (+2% against -2% a year earlier). Lantheus Holdings is more profitable, with an operating margin of 8.3% against -19.7%.
Where the money goes: LNTH and MYGN
Lantheus Holdings (LNTH) · Q3 2026
Lantheus Holdings, Q3 2026: revenue $390M (+2% year over year), operating margin 8.3%, net earnings $22.4M, operating cash flow $102M. The chart follows the revenue to costs, profit and cash.
Myriad Genetics (MYGN) · Q3 2026
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Lantheus Holdings (LNTH) | Myriad Genetics (MYGN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $390M | $203M |
| Revenue growth, Y/Y | +2% | -2% |
| Gross margin | 62.4% | — |
| Operating margin | 8.3% | -19.7% |
| Net earnings | $22.4M | −$43.9M |
| Net margin | 5.7% | -21.7% |
| Operating cash flow | $102M | −$6.5M |
| Free cash flow | $99.9M | — |
| Market value | $6.9B | — |
| P/E | 25.5× | — |
| Analysts’ mean target | $106.99 | — |
Where the revenue comes from
Lantheus Holdings
- PYLARIFY: $239M (61%)
- Definity: $85.7M (22%)
- Neuraceq: $45.6M (12%)
- Strategic Partnerships and Other: $19.7M (5%)
Myriad Genetics
- Cancer Care Continuum: $124M (61%)
- Mental Health: $39.5M (19%)
- Prenatal Health: $39.3M (19%)
Questions
Which is bigger, Lantheus Holdings or Myriad Genetics?
Lantheus Holdings is the larger company: $390M of revenue in its latest quarter (Q3 2026) against $203M for Myriad Genetics (Q3 2026).
Is Lantheus Holdings or Myriad Genetics growing faster?
Lantheus Holdings is growing faster (+2% against -2% a year earlier).
Which is more profitable, Lantheus Holdings or Myriad Genetics?
Lantheus Holdings is more profitable, with an operating margin of 8.3% against -19.7%.
More: Lantheus Holdings earnings · how Lantheus Holdings makes money · Myriad Genetics earnings · how Myriad Genetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.